Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INCB018424 · 1 trial · 1 indication
The ACR 20 is defined as ≥ 20% improvement in tender joint count plus ≥ 20% improvement in swollen joint count plus ≥ 20% improvement in 3 of the following 5 criteria: subject's assessment of pain, Subject's global assessment of disease activity (PGA), Physician's global assessment of disease activity (PHGA), subject's self-assessed disability Health Assessment Questionnaire (HAQ), and Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), whichever shows the greatest change.
| Arm | Type | Description |
|---|---|---|
| Cohort 1: Treatment Group A | EXPERIMENTAL | INCB018424 15 mg twice daily (BID) or matching placebo |
| Cohort 2: Treatment Group B | EXPERIMENTAL | INCB018424 5 mg BID or matching placebo |
| Cohort 2: Treatment Group C | EXPERIMENTAL | INCB018424 25 mg BID or matching placebo |
| Cohort 2: Treatment Group D | EXPERIMENTAL | INCB018424 50 mg once daily (QD) or matching placebo |
| Placebo | PLACEBO_COMPARATOR | Matching placebo, oral |
| Name | Type | Description |
|---|---|---|
| INCB018424 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: 1. Established diagnosis of rheumatoid arthritis 2. Patients receiving methotrexate must be treated with for at least 6 months and receiving a stable weekly dose between 10 and 25 mg for at least 8 consecutive weeks prior to study entry. Exclusion Criteria: 1. Patients who hav...
Top 20 of 28 competitors
INCB018424 is an investigational small molecule being studied for the treatment of active rheumatoid arthritis. It is being developed by Incyte Corporation and is currently in Phase 2 clinical development. The drug is administered orally and has been evaluated in a placebo-controlled clinical trial.
INCB018424 is a small molecule therapeutic being developed for rheumatoid arthritis. Its specific molecular target has not been disclosed in available clinical trial information. The drug is currently in Phase 2 development by Incyte Corporation for the treatment of active rheumatoid arthritis.
INCB018424 is being developed by Incyte Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol INCY. The drug is an investigational small molecule in Phase 2 clinical development for the treatment of active rheumatoid arthritis.
INCB018424 is in Phase 2 clinical development. It is an investigational drug being studied for the treatment of active rheumatoid arthritis. The drug has completed a Phase 2 clinical trial and is not yet approved by regulatory authorities.
INCB018424 has been studied in a completed Phase 2 clinical trial identified as NCT00550043. This trial explored the safety, tolerability, and efficacy of a 4-week course of INCB018424 in 50 subjects with active rheumatoid arthritis. The study was conducted in the United States and Poland.
INCB018424 is the development code for a drug that is also known as ruxolitinib. It is a small molecule being developed by Incyte Corporation for the treatment of active rheumatoid arthritis. The drug is currently in Phase 2 clinical development.